Concord Biotech's Q4 Net Profit Soars to ₹1.4 Billion, Announces ₹10.70 Dividend May 30, 2025
Concord Biotech Reports Robust Q4 Performance with Surge in Profits and Revenue, Recommends Dividend May 29, 2025
Concord Biotech's Dholka Facility Receives Form 483 After USFDA Inspection May 05, 2025
More news about Concord Biotech
02May 25
Concord Biotech's Dholka API Facility Receives FDA Form 483 After Inspection
Concord Biotech Limited's API facility in Dholka, Gujarat, underwent a USFDA inspection from April 28 to May 2, 2025. The inspection concluded with a Form 483 containing four observations, which the company claims are procedural and not related to data integrity. Concord Biotech plans to respond to the USFDA within the required timeframe and is confident in addressing the observations quickly.
09Apr 25
Concord Biotech Secures USFDA Approval for Teriflunomide Tablets, Eyeing $402.00 Million US Market
Concord Biotech Limited has received final USFDA approval to market Teriflunomide Tablets in 7 mg and 14 mg strengths for treating relapsing forms of multiple sclerosis. The US market for this drug is estimated at $402 million, with a global market of $908 million. This approval demonstrates Concord Biotech's capability in developing complex generic drugs and positions the company for expansion in the US pharmaceutical market.
08Apr 25
Concord Biotech Secures FDA Approval for Teriflunomide Tablets, Eyeing $402 Million US Market
Concord Biotech Limited has received final approval from the USFDA to market Teriflunomide tablets in 7 mg and 14 mg strengths for treating relapsing forms of multiple sclerosis. The U.S. market for this drug is valued at approximately $402 million, with a global market of $908 million. This approval marks a significant milestone for the company's expansion into the U.S. pharmaceutical market.
25Mar 25
Concord Biotech Launches Injectable Production at New Valthera Facility
Concord Biotech Limited has successfully commissioned and commenced injectable production at its new Unit-4 manufacturing facility in Valthera on March 25, 2025. The state-of-the-art facility, designed to meet international standards, is equipped with advanced technology for high-quality injectable products. This strategic expansion is expected to enhance the company's manufacturing capabilities and market position in the pharmaceutical sector.
20Feb 25
Concord Biotech Strengthens Global Standing with Successful MFDS Inspection
Concord Biotech Limited successfully completed an inspection by the Ministry of Food and Drug Safety (MFDS) at its Manufacturing Unit I in Dholka, Gujarat. The inspection, conducted from February 18 to February 20, 2025, focused on the company's API facility. This achievement is expected to reinforce Concord Biotech's quality assurance standards, potentially enhance its access to global markets, and strengthen its position in the biotech industry.